SYNGENE - Swing Trade Analysis with AI Signals

Last Updated Time : 20 Dec 25, 07:02 am

Swing Trade Rating: 3.3

📊 SYNGENE presents a cautious outlook for swing trading. The stock is priced at ₹655, slightly above its 50 DMA (₹644) but below its 200 DMA (₹672), showing mixed technical signals. RSI (57.3) is neutral, while MACD (1.83) suggests mild bullish momentum. Fundamentals are stretched with a high P/E (60.3 vs industry 46.0) and PEG ratio (46.8), while profitability has weakened (PAT down from ₹74 Cr. to ₹66.2 Cr., -31.5% variation). Strong liquidity and low debt (0.07) provide stability, but valuations limit upside potential.

✅ Optimal Entry Price: Around ₹640–650, near 50 DMA support.

🚪 Exit Strategy: If already holding, consider exiting near ₹680–700 (resistance zone) or on weakness below ₹630.

Positive

• 💡 Low debt-to-equity (0.07) ensures financial stability.
• 💡 Strong liquidity with volumes above weekly average.
• 💡 DII holdings increased (+0.57%), showing domestic institutional confidence.

Limitation

• ⚠️ High P/E (60.3) compared to industry average (46.0).
• ⚠️ PEG ratio of 46.8 indicates poor growth-adjusted valuation.
• ⚠️ ROCE (12.8%) and ROE (9.78%) are modest for the sector.

Company Negative News

• 📉 PAT declined from ₹74 Cr. to ₹66.2 Cr. (-31.5%).
• 📉 FII holdings decreased (-0.20%), showing reduced foreign investor interest.

Company Positive News

• 📈 DII holdings increased (+0.57%), reflecting domestic support.
• 📈 EPS of ₹10.9 provides consistent earnings base.

Industry

• 🏭 Industry P/E at 46.0 highlights SYNGENE’s premium valuation.
• 🏭 Biotech & pharma sector remains resilient with steady demand.

Conclusion

🔎 SYNGENE is a moderately suitable candidate for swing trading. Entry near ₹640–650 offers a favorable setup, while upside is capped around ₹680–700 due to stretched valuations and declining profitability. Best suited for cautious traders seeking short-term rebounds rather than aggressive momentum plays.

Would you like me to also compare SYNGENE’s swing trade potential with another biotech stock to see relative opportunities?